Holen Sie sich die Stockscreener-App
1.86
14.11%
0.23
Vorhandelsmarkt:
1.93
0.07
+3.76%
Schlusskurs vom Vortag:
$1.63
Offen:
$1.65
24-Stunden-Volumen:
94,408
Relative Volume:
1.70
Marktkapitalisierung:
$13.60M
Einnahmen:
$10.16M
Nettoeinkommen (Verlust:
$-47.57M
KGV:
-0.2257
EPS:
-8.24
Netto-Cashflow:
$-42.73M
1W Leistung:
+43.08%
1M Leistung:
-19.83%
6M Leistung:
-62.20%
1J Leistung:
-87.15%
1-Tages-Spanne:
$1.65
$1.89
1-Wochen-Bereich:
$1.30
$1.89
52-Wochen-Spanne:
$1.02
$16.99
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Vergleichen Sie CRIS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.86 | 13.60M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Curis (NASDAQ:CRIS) Coverage Initiated by Analysts at StockNews.com - Defense World
Curis (NASDAQ:CRIS) Now Covered by StockNews.com - Defense World
Curis, Inc. and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration - marketscreener.com
Form DEFA14A CURIS INC - StreetInsider
Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call Transcript - MSN
Curis stock plunges to 52-week low at $1.1 amid sharp decline - Investing.com Canada
Curis stock plunges to 52-week low at $1.1 amid sharp decline By Investing.com - Investing.com South Africa
Truist Removes Price Target on Curis Due to Volatility, Low Share Price; Price Target Was $26, Buy Rating Kept - marketscreener.com
Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline - MSN
HC Wainwright Forecasts Curis’ Q1 Earnings (NASDAQ:CRIS) - Defense World
Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher - Yahoo
Curis to Present at Upcoming Healthcare Conference in April - The Malaysian Reserve
Curis to Present at Upcoming Healthcare Conference in April 2025 - BioSpace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS) - simplywall.st
HC Wainwright Lowers Curis (NASDAQ:CRIS) Price Target to $16.00 - The AM Reporter
Curis stock price target cut to $16 by H.C. Wainwright - Investing.com Australia
Curis stock plunges to 52-week low at $1.97 amid market challenges - Investing.com
Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Yahoo
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30% - simplywall.st
Curis: Q4 Earnings Snapshot - CT Insider
Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... - Yahoo Finance
Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright - Defense World
Curis Inc. Reports Q4 2024 Progress and Financials - TipRanks
Curis Inc. Earnings Call: Progress Amidst Challenges - TipRanks
Curis eyes accelerated approval for cancer drug emavusertib By Investing.com - Investing.com South Africa
Earnings call transcript: Curis Q4 2024 reveals reduced losses By Investing.com - Investing.com India
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Curis eyes accelerated approval for cancer drug emavusertib - Investing.com India
Curis Provides Fourth Quarter 2024 Business Update - PR Newswire
Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Quantisnow
Curis Inc Entered A Purchase Agreement To Sell 2 Million Shares Of Common Stock - MarketScreener
Indo-Asian News Service - Indo-Asian News Service (IANS)
Biotech Alert: Curis Sets Date for Q4 EarningsKey Updates on IRAK4 Inhibitor Program Expected - Stock Titan
Curis stock hits 52-week low at $2.54 amid sharp annual decline - Investing.com Australia
Curis stock hits 52-week low at $2.54 amid sharp annual decline By Investing.com - Investing.com South Africa
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):